The antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. Biocon and US firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with ...
CCI orders antitrust probe into Roche cancer drug
Biocon and Mylan told CCI that Roche misled doctors, regulators to thwart competition to Trastuzumab